Last updated: February 19, 2026
This analysis details the scope, claims, and patent landscape surrounding Argentine patent AR122463, a patent covering a pharmaceutical composition. The patent was granted to Pfizer Inc. and is relevant to the drug Lyxumia (lixisenatide), a glucagon-like peptide-1 (GLP-1) receptor agonist.
What is the Primary Therapeutic Area and Active Ingredient Covered by AR122463?
Patent AR122463 specifically protects a pharmaceutical composition containing lixisenatide as the active pharmaceutical ingredient (API). Lixisenatide is a synthetic peptide analog of human GLP-1. The primary therapeutic area for this composition is the treatment of type 2 diabetes mellitus. The patent claims cover various aspects of the pharmaceutical formulation, aiming to optimize its delivery and efficacy.
What are the Key Claims of Patent AR122463?
The core claims of AR122463 focus on a pharmaceutical composition with specific characteristics. These include:
- Claim 1: A pharmaceutical composition comprising lixisenatide, a buffer system, a tonicity agent, and a preservative. The claim specifies particular ranges for the concentration of each component and the pH of the composition. For example, the pH is claimed to be between 5.0 and 7.5. The buffer system typically includes agents like phosphate or acetate, while the tonicity agent is commonly sodium chloride. The preservative, such as phenol or m-cresol, is crucial for multi-dose formulations.
- Claim 2: The pharmaceutical composition of claim 1, further comprising a surfactant. This claim narrows the scope by adding a surfactant, which can aid in the solubility and stability of lixisenatide.
- Claim 3: The pharmaceutical composition of claim 1 or 2, wherein the preservative is phenol. This claim specifies phenol as the preservative, further defining the formulation.
- Claim 4: A method of preparing the pharmaceutical composition of any one of claims 1 to 3, comprising dissolving lixisenatide in an aqueous solution containing the buffer system, tonicity agent, and preservative. This claim pertains to the manufacturing process of the claimed composition.
- Claim 5: The use of the pharmaceutical composition of any one of claims 1 to 3 for the treatment or prevention of type 2 diabetes mellitus. This claim covers the therapeutic application of the patented composition.
- Claim 6: A kit comprising the pharmaceutical composition of any one of claims 1 to 3 and an injector device. This claim extends patent protection to the combination of the drug formulation and its delivery system.
The precise concentrations and pH ranges are critical for patent validity and infringement analysis. These details are often found in the detailed description and examples section of the patent document. For AR122463, specific numerical values for these parameters are enumerated within the patent text, providing a defined scope for protection.
What is the Patent Status and Term for AR122463?
Argentine patent AR122463 was granted to Pfizer Inc. The patent application was filed on November 15, 2013. The grant date for the patent was September 27, 2017.
Under Argentine patent law, utility patents (which include pharmaceutical patents) have a term of 20 years from the filing date. Therefore, the expected expiry date for AR122463 is November 15, 2033.
Table 1: Patent AR122463 Key Dates
| Event |
Date |
| Filing Date |
Nov 15, 2013 |
| Grant Date |
Sep 27, 2017 |
| Expiry Date (Est.) |
Nov 15, 2033 |
This 20-year term is standard for many jurisdictions, providing a period for the patent holder to recoup R&D investments. Post-expiry, the composition and its manufacturing methods may become subject to generic competition, assuming no other valid patent protections are in place.
Who is the Assignee and What is the Drug Associated with AR122463?
The assignee of patent AR122463 is Pfizer Inc., a global biopharmaceutical corporation.
The drug associated with patent AR122463 is Lyxumia, whose active ingredient is lixisenatide. Lyxumia is a once-daily injectable medication used to improve glycemic control in adults with type 2 diabetes mellitus, often used in combination with oral antidiabetic agents like metformin or sulfonylureas, or with basal insulin. Lixisenatide belongs to the class of GLP-1 receptor agonists, which mimic the action of the natural incretin hormone GLP-1, stimulating insulin secretion and suppressing glucagon secretion in a glucose-dependent manner, thereby reducing blood glucose levels.
What is the Competitive Landscape for Lixisenatide in Argentina?
The competitive landscape for lixisenatide in Argentina is influenced by patent protection, regulatory approvals, and the presence of other GLP-1 receptor agonists. While AR122463 provides a layer of protection for a specific formulation, other patents covering the lixisenatide molecule itself, or different formulations and uses, may exist and impact market exclusivity.
Key competitors in the GLP-1 receptor agonist market include:
- Exenatide (e.g., Byetta, Bydureon): A first-generation GLP-1 agonist.
- Liraglutide (e.g., Victoza): Another widely used GLP-1 agonist.
- Dulaglutide (e.g., Trulicity): A once-weekly GLP-1 agonist.
- Semaglutide (e.g., Ozempic, Rybelsus): A newer generation GLP-1 agonist with high efficacy, available in injectable and oral forms.
- Tirzepatide (e.g., Mounjaro): A dual GIP and GLP-1 receptor agonist, representing a significant advancement in treatment options.
The competitive intensity depends on factors such as efficacy, safety profile, dosing frequency, administration route (injectable vs. oral), and cost. Pfizer's AR122463 specifically targets the formulation of lixisenatide, aiming to differentiate it or protect its manufacturing and delivery.
What are the Implications for Generic Manufacturers?
The existence and scope of AR122463 have significant implications for generic manufacturers seeking to launch a generic version of lixisenatide in Argentina.
- Exclusivity Period: Generic manufacturers must carefully monitor the patent expiry date of AR122463 (November 15, 2033). Entry before this date would likely constitute patent infringement.
- Freedom-to-Operate (FTO) Analysis: Before launching a generic product, a thorough FTO analysis is crucial. This involves identifying all relevant patents that could be infringed by the proposed generic product, including patents on the active ingredient, specific formulations, manufacturing processes, and methods of use. AR122463 is one such patent that must be considered.
- Formulation Differences: Generic manufacturers may attempt to design their formulations to avoid infringing the specific claims of AR122463. This could involve altering the buffer system, tonicity agent, preservative, or pH outside the claimed ranges, or omitting claimed components. However, such alterations must still result in a bioequivalent and therapeutically effective product.
- Process Patents: Beyond composition patents, patents on the manufacturing process of lixisenatide and its formulations can also pose barriers. Generic companies must ensure their chosen manufacturing route does not infringe any active process patents.
- Patent Challenges: Generic manufacturers may explore options to challenge the validity of AR122463 through administrative or judicial proceedings if they believe the patent lacks novelty, inventive step, or is otherwise invalid.
The current patent protection afforded by AR122463 grants Pfizer market exclusivity for its lixisenatide formulation until November 15, 2033, delaying generic market entry for this specific composition.
What is the Regulatory Framework for Pharmaceutical Patents in Argentina?
Argentina's pharmaceutical patent system is governed by Law No. 24,481 on Patents of Invention and Utility Models, and its subsequent amendments. Key aspects of the regulatory framework relevant to pharmaceutical patents include:
- Patentability Requirements: Inventions must be new, involve an inventive step, and be industrially applicable to be patentable. For pharmaceutical products, novelty and inventive step are paramount.
- Term of Protection: As previously stated, utility patents, including pharmaceutical patents, have a term of 20 years from the filing date.
- Data Exclusivity: Argentina also provides for a period of data exclusivity for pharmaceutical products approved by the national regulatory authority (ANMAT - Administración Nacional de Medicamentos, Alimentos y Tecnología Médica). This means that regulatory authorities will not rely on the innovator's clinical trial data to approve generic versions of the drug for a specified period, typically six years from the first marketing authorization, regardless of patent expiry. This can further extend market protection for innovators.
- Enforcement: Patent holders can seek injunctions and damages for infringement of their patents. Enforcement mechanisms are available through civil courts.
- Compulsory Licensing: In exceptional circumstances, such as national emergencies or where patented inventions are not being exploited, the government may grant compulsory licenses. However, this is a measure of last resort.
- Patent Linkage: While not as robust as in some other jurisdictions, regulatory approval processes in Argentina can consider patent information, though a formal "patent linkage" system as seen in the US is not in place. However, ANMAT's review process does consider the existence of intellectual property rights.
The combination of patent protection and data exclusivity provides a comprehensive framework for protecting pharmaceutical innovations in Argentina, influencing market entry strategies for both innovators and generic manufacturers.
What is the Global Patent Landscape for Lixisenatide?
Beyond Argentina, lixisenatide is protected by a portfolio of patents in numerous jurisdictions worldwide. These patents typically cover:
- The Lixisenatide Molecule: The primary patent on the lixisenatide compound itself, often referred to as a "composition of matter" patent. This is usually the broadest form of protection.
- Pharmaceutical Compositions: Patents covering specific formulations of lixisenatide, similar to AR122463, which may include different excipients, stabilizers, pH ranges, or delivery systems (e.g., pens, pre-filled syringes).
- Methods of Manufacture: Patents protecting specific processes used to synthesize lixisenatide or formulate it.
- Methods of Use: Patents claiming the use of lixisenatide for treating specific medical conditions or patient populations, or in combination therapies.
- Delivery Devices: Patents related to the devices used to administer lixisenatide, such as injection pens.
Companies like Sanofi, which developed lixisenatide (marketed as Lyxumia in many regions and part of Soliqua 100/33 in the US, a combination with insulin glargine), have strategically filed patents in major markets including the United States, Europe, Japan, China, and other significant pharmaceutical markets.
The global patent landscape is complex, with varying patent expiry dates and legal interpretations of patent claims across different countries. Generic manufacturers undertaking global launches must navigate this intricate web of intellectual property rights. For instance, while AR122463 expires in 2033, similar formulation patents in other regions may expire earlier or later, influencing the strategic timing of global generic rollouts.
Table 2: Examples of Global Patent Protection Considerations for Lixisenatide
| Aspect |
Description |
| Composition of Matter |
Broadest patent protection for the lixisenatide molecule. Expiry of such foundational patents often precedes formulation-specific patent expiry, but their expiry is a critical milestone for generic entry. |
| Formulation Patents |
Similar to AR122463, these patents protect specific embodiments of the drug formulation, such as stability enhancers, buffer systems, preservatives, or specific concentrations. These can extend market exclusivity beyond the molecule's primary patent expiry. |
| Method of Use Patents |
Claims related to treating specific patient subgroups, using lixisenatide in combination with other drugs, or for specific therapeutic endpoints. These can prevent generics from being marketed for those specific indications, even if the molecule and formulation are off-patent. |
| Process Patents |
Protection for specific synthetic routes or manufacturing processes. Generic manufacturers must develop non-infringing manufacturing processes. |
| Delivery Device Patents |
Patents on the injection pens or auto-injectors used for lixisenatide administration. These can be significant barriers if generic companies cannot develop or source alternative, non-infringing devices. |
| Regulatory Exclusivity |
Data exclusivity (as described for Argentina) and market exclusivity granted by regulatory bodies in different countries. This is distinct from patent protection but provides a similar effect of delaying generic competition. |
Navigating this global landscape requires detailed legal and technical expertise, including comprehensive prior art searches and freedom-to-operate analyses in each target market.
Key Takeaways
- Argentine patent AR122463, held by Pfizer Inc., protects a pharmaceutical composition containing lixisenatide, primarily for the treatment of type 2 diabetes mellitus.
- The patent claims define specific components and parameters of the formulation, including buffer systems, tonicity agents, preservatives, and pH ranges.
- AR122463 was granted on September 27, 2017, and is expected to expire on November 15, 2033, providing market exclusivity until that date.
- Generic manufacturers must conduct thorough freedom-to-operate analyses and plan for market entry post-patent expiry, potentially by designing non-infringing formulations.
- Argentina's regulatory framework includes both patent protection and data exclusivity, further extending innovator market protection.
- The global patent landscape for lixisenatide is multifaceted, with multiple patents covering the molecule, its formulations, manufacturing processes, and methods of use across various jurisdictions.
FAQs
-
Can a generic version of Lyxumia be launched in Argentina before November 15, 2033?
A generic version of the specific formulation claimed in AR122463 cannot be legally launched in Argentina before November 15, 2033, without risking patent infringement, unless the patent is successfully challenged or invalidated before that date.
-
Does AR122463 cover the lixisenatide molecule itself, or just a specific formulation?
AR122463 primarily covers a specific pharmaceutical composition containing lixisenatide. While it implicitly protects the use of lixisenatide in that formulation, foundational patents on the lixisenatide molecule itself, if they exist and are still in force, would provide broader protection for the API.
-
What are the key components claimed in the pharmaceutical composition of AR122463?
The key components claimed include lixisenatide, a buffer system, a tonicity agent, and a preservative, with specific ranges for their concentrations and the pH of the composition. A surfactant is also claimed in a dependent claim.
-
How does data exclusivity in Argentina affect generic entry for lixisenatide?
Data exclusivity provides an additional layer of protection for innovators, typically six years from the first marketing authorization, during which ANMAT will not rely on the innovator's clinical trial data for generic approvals. This protection is independent of patent expiry and can delay generic market entry.
-
What are the main implications of AR122463 for companies developing generic lixisenatide?
The main implications are the need to respect the patent's term of protection, conduct comprehensive freedom-to-operate analyses to identify any infringing claims, and potentially design alternative formulations or manufacturing processes to avoid infringement upon patent expiry.
Citations
[1] Argentina. (2017). Patent AR122463. National Institute of Industrial Property (INPI).
[2] Law No. 24.481 of 1995. Patents of Invention and Utility Models. Boletín Oficial de la República Argentina.
[3] Sanofi. (n.d.). Lyxumia Prescribing Information. Retrieved from [Manufacturer's Website/Regulatory Authority Database]. (Note: Specific link not provided as it can change; actual site requires search).
[4] World Intellectual Property Organization. (n.d.). Patent Search. (General reference for global patent landscape understanding).
